The Opioid Withdrawal Syndrome market growth is driven by factors like increase in the prevalence of Opioid Withdrawal Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Opioid Withdrawal Syndrome market report also offers comprehensive insights into the Opioid Withdrawal Syndrome market size, share, Opioid Withdrawal Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Opioid Withdrawal Syndrome market size growth forward.
Some of the key highlights from the Opioid Withdrawal Syndrome Market Insights Report:
- Several key pharmaceutical companies, including Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, and others, are developing novel products to improve the Opioid Withdrawal Syndrome treatment outlook.
- The total Opioid Withdrawal Syndrome market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Opioid Withdrawal Syndrome market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Opioid Withdrawal Syndrome Market Landscape
Opioid Withdrawal Syndrome Overview
According to the American Addiction Centers, when the use of opiate drugs is stopped, it may produce several withdrawal symptoms and collectively these symptoms are called Opiate Withdrawal Syndrome (OWS). Opiate withdrawal symptoms may range from mild to severe, depending on how dependent the individual is on an opioid drug. Early withdrawal symptoms usually start within 6‒12 h for short-acting opiates, and they start within 30 h for longer-acting ones. The early symptoms include tearing, muscle aches, agitation, trouble falling and staying asleep, excessive yawning, anxiety, nose running, sweats, racing heart, hypertension, and fever. Late withdrawal symptoms start within 72 h and usually last a week. The symptoms include nausea and vomiting, diarrhea, goose bumps, stomach cramps, depression, and drug cravings. Some of the psychological withdrawal symptoms and cravings for opioid drugs may persist longer than a week in some cases.
Each opiate drug has a unique half-life and as a result, withdrawal symptoms may start at different times, depending on the drug and method in which it is taken. The withdrawal symptoms are generally not life-threatening, but it causes tremendous psychological and physical disturbance that often people start reuse of opioids to avoid withdrawal symptoms. This leads to a continuous cycle of stopping and resuming drug use, which makes it difficult to quit later on. The use of opioids leads to the suppression of brain stem function. The brain stem tries to overcome this suppression by increasing output, sudden stop of opioid use causes ‘fight or flight’ output from the brainstem and leads to the symptoms of Opioid Withdrawal Syndrome.
Opioid Withdrawal Syndrome Diagnosis
Although there is no diagnostic test for opioid withdrawal, urine toxicology must be checked to rule out withdrawal from any other drugs or combination of drugs. ECG, complete blood count (CBC), blood alcohol level, and basic metabolic panel (BMP) should also be done. COWS (Clinical Opioid Withdrawal Scale) assessment for opioid withdrawal is commonly used to determine the severity of opioid withdrawal.
Opioid Withdrawal Syndrome Treatment
When opioid withdrawal signs are present, pharmacological management of opioid withdrawal is done via one of the following which includes gradual cessation of an opioid agonist (methadone); short-term use of a partial mu-opioid agonist (buprenorphine), and detoxification using opioid antagonists (naltrexone and naloxone). Other off-label treatments include the use of clonidine, which is used extensively to reduce blood pressure in Opioid Withdrawl Syndrome. Symptomatic treatment in opioid withdrawal includes loperamide for diarrhea, promethazine for nausea/vomiting, and ibuprofen for myalgia.
Do you know the treatment paradigms for different countries? Download our Opioid Withdrawal Syndrome Market Sample Report
Opioid Withdrawal Syndrome Epidemiology Segmentation
DelveInsight’s Opioid Withdrawal Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Opioid Withdrawal Syndrome historical patient pools and forecasted Opioid Withdrawal Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Opioid Withdrawal Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Opioid Withdrawal Syndrome Prevalence
- Age-Specific Opioid Withdrawal Syndrome Prevalence
- Gender-Specific Opioid Withdrawal Syndrome Prevalence
- Diagnosed and Treatable Cases of Opioid Withdrawal Syndrome
Visit for more @ Opioid Withdrawal Syndrome Epidemiological Insights
Opioid Withdrawal Syndrome Treatment Market
The Opioid Withdrawal Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Opioid Withdrawal Syndrome market trends by analyzing the impact of current Opioid Withdrawal Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Opioid Withdrawal Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Opioid Withdrawal Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Opioid Withdrawal Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Opioid Withdrawal Syndrome Key Companies
- Chiesi Farmaceutici S.p.A.
- BioXcel Therapeutics
- Aphios Pharmaceutical
Opioid Withdrawal Syndrome Therapy Assessment
CHF-6563: Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici is developing a sublingual formulation of CHF-6563. A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study is being developed by Chiesi Farmaceutici S.p.A. to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome.
BXCL501: BioXcel Therapeutics
BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia. BXCL501 is being evaluated in the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.
For more information, visit Opioid Withdrawal Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Opioid Withdrawal Syndrome Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Opioid Withdrawal Syndrome, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Opioid Withdrawal Syndrome epidemiology in the 7MM
- Opioid Withdrawal Syndrome marketed and emerging therapies
- Opioid Withdrawal Syndrome companies
- Opioid Withdrawal Syndrome market drivers and barriers
Key Questions Answered in the Opioid Withdrawal Syndrome Market Report 2032:
- What was the Opioid Withdrawal Syndrome market share distribution in 2019, and how would it appear in 2032?
- What is the total Opioid Withdrawal Syndrome market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Opioid Withdrawal Syndrome market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Opioid Withdrawal Syndrome market projected to expand at 7MM?
Table of Contents:
1 Opioid Withdrawal Syndrome Market Key Comprehensive Insights
2 Opioid Withdrawal Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Opioid Withdrawal Syndrome
4 Opioid Withdrawal Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Opioid Withdrawal Syndrome
6 Opioid Withdrawal Syndrome Epidemiology and Market Methodology
7 Opioid Withdrawal Syndrome Epidemiology and Patient Population
8 Opioid Withdrawal Syndrome Patient Journey
9 Opioid Withdrawal Syndrome Treatment Algorithm, Opioid Withdrawal Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Opioid Withdrawal Syndrome Clinical Trials
11 Opioid Withdrawal Syndrome Marketed Therapies
12 Opioid Withdrawal Syndrome Emerging Therapies
13 Opioid Withdrawal Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Opioid Withdrawal Syndrome
16 Opioid Withdrawal Syndrome Market Key Opinion Leaders Reviews
18 Opioid Withdrawal Syndrome Market Drivers
19 Opioid Withdrawal Syndrome Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Opioid Withdrawal Syndrome Epidemiology 2032
DelveInsight’s “Opioid Withdrawal Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Opioid Withdrawal Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Opioid Withdrawal Syndrome Pipeline 2023
“Opioid Withdrawal Syndrome Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Opioid Withdrawal Syndrome market. A detailed picture of the Opioid Withdrawal Syndrome pipeline landscape is provided, which includes the disease overview and Opioid Withdrawal Syndrome treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/